India, Jan. 28 -- Abbott, the global healthcare company, has announced the launch of Navitor Vision in India for the treatment of patients with symptomatic severe aortic stenosis who are at high or extreme surgical risk.

The device is the latest iteration of the company's Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system. The Navitor platform, known for its stable delivery, remarkable performance, and future readiness, has been enhanced with three large Vision markers for improved visibility and easier valve deployment during a TAVI/TAVR procedure. These markers help interventionists implant the device more accurately, while making the TAVI valve easier to see during the procedure.

Aortic stenosis is one of ...